Prostate, Hepatic, and Osseous Lesions on 18F-DCFPyL PET/CT
Prostate-specific membrane antigen (PSMA) targeting PET imaging has an established role in prostate carcinoma for staging, recurrence evaluation, and selection for PSMA-targeted radiopharmaceutical therapy. We report a case with PSMA avid prostate, hepatic, and osseous lesions in a patient with synchronous malignancies complicating management.
Authors
- Jiannan Li (ORCID: https://orcid.org/0000-0001-9744-7666)
- Sayan Manna (ORCID: https://orcid.org/0000-0001-8649-2592)
- Ashwin Singh Parihar (ORCID: https://orcid.org/0000-0002-7983-4117)
- Saurabh Jindal (ORCID: https://orcid.org/0000-0003-1711-9895)
- James E. Kelly
- Louis Dehner
Institutions
- Washington University in St. Louis (US)
- Active Medicine (United Kingdom) (GB)
- Mallinckrodt (Ireland) (IE)
Publication Details
- Journal
- Clinical nuclear medicine open.
- Published
- 2026-05-18
- DOI
- https://doi.org/10.1097/nm9.0000000000000067
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00